IP Library Granted Patent US 8,772,264
Granted Patent B2
US 8,772,264 · App. 13/388,751 · Granted Jul 8, 2014

Methods of treating hematologic cancers

Inventors: Neil E. Kay (St. Louis Park, MN); Tait D. Shanafelt (Rochester, MN)
Assignee: Mayo Foundation for Medical Education and Research
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,772,264
App. No.
13/388,751
Granted
Jul 8, 2014
Kind
B2
Abstract

This disclosure relates to the treatment of hematologic cancers, for example, cancers of the blood, by methods that include administration of EGCG and at least one of a purine nucleoside analog and an alkylating agent. In particular, methods of treating chronic lymphocytic leukemia (CLL) and acute lymphocytic leukemia (ALL) are described.

Claims (11)

1. A method of treating a hematologic cancer in a subject having a hematologic cancer comprising the steps of:

(a) administering to the subject an effective amount of epigallocatechin gallate (EGCG), or a pharmaceutically acceptable salt, ester, or salt of an ester thereof; and

(b) administering to the subject an effective amount of fludarabine, or a pharmaceutically acceptable salt, ester, or salt of an ester thereof, and chlorambucil, or a pharmaceutically acceptable salt, ester, or salt of an ester thereof.

2. The method of claim 1 , wherein the EGCG, fludarabine, and chlorambucil are admixed prior to administration.

3. The method of claim 1 , wherein the EGCG and the chlorambucil are admixed prior to administration.

4. The method of claim 1 , wherein the EGCG and the fludarabine are admixed prior to administration.

5. The method of claim 1 , wherein the EGCG and at least one of the fludarabine and the chlorambucil are administered concurrently.

6. The method of claim 1 , wherein the fludarabine and the chlorambucil are admixed prior to administration.

7. The method of claim 1 , wherein the EGCG and at least one of the fludarabine and the chlorambucil are administered sequentially.

8. The method of claim 1 , wherein the hematologic cancer is chosen from chronic lymphocytic leukemia and acute lymphoblastic leukemia.

9. A method of treating chronic lymphocytic leukemia in a subject having a hematologic cancer, the method comprising administering to the subject a composition comprising EGCG, or a pharmaceutically acceptable salt, ester, or salt of an ester thereof, flurdarabine, or a pharmaceutically acceptable salt, ester, or salt of an ester thereof, and chlorambucil, or a pharmaceutically acceptable salt, ester, or salt of an ester thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2012
From: KAY, NEIL E.; SHANAFELT, TAIT D.
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 028106/0404 →
CONFIRMATORY LICENSE Recorded Mar 5, 2012
From: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 027802/0425 →
Continuity (2)
Provisional Application 61231052 · Aug 4, 2009
Related Publication 20120190638A1 · Jul 26, 2012